NASDAQ:PRAH - PRA Health Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$102.52 +1.32 (+1.30 %)
(As of 07/22/2018 04:00 PM ET)
Previous Close$102.52
Today's Range$101.50 - $102.93
52-Week Range$73.05 - $102.93
Volume366,995 shs
Average Volume703,910 shs
Market Capitalization$6.57 billion
P/E Ratio31.45
Dividend YieldN/A
Beta0.49
PRA Health Sciences logoPRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200

Debt

Debt-to-Equity Ratio1.29
Current Ratio0.83
Quick Ratio0.83

Price-To-Earnings

Trailing P/E Ratio31.45
Forward P/E Ratio26.84
P/E Growth1.58

Sales & Book Value

Annual Sales$2.26 billion
Price / Sales2.91
Cash Flow$4.6963 per share
Price / Cash21.83
Book Value$14.78 per share
Price / Book6.94

Profitability

EPS (Most Recent Fiscal Year)$3.20
Net Income$86.92 million
Net Margins4.07%
Return on Equity23.06%
Return on Assets6.84%

Miscellaneous

Employees15,800
Outstanding Shares64,080,000
Market Cap$6,569.07

PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) posted its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.84 by $0.01. The medical research company had revenue of $701.80 million for the quarter, compared to analyst estimates of $694.73 million. PRA Health Sciences had a net margin of 4.07% and a return on equity of 23.06%. PRA Health Sciences's quarterly revenue was up 43.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 earnings per share. View PRA Health Sciences' Earnings History.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for PRA Health Sciences.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $4.00-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.12. The company issued revenue guidance of $2.84-2.95 billion, compared to the consensus revenue estimate of $2.91 billion.

What price target have analysts set for PRAH?

10 brokers have issued 12-month price objectives for PRA Health Sciences' shares. Their forecasts range from $86.00 to $115.00. On average, they expect PRA Health Sciences' share price to reach $97.80 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Ratings for PRA Health Sciences.

What is the consensus analysts' recommendation for PRA Health Sciences?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting PRA Health Sciences?

PRA Health Sciences saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 2,898,254 shares, a decrease of 31.5% from the June 15th total of 4,229,589 shares. Based on an average daily trading volume, of 1,135,267 shares, the short-interest ratio is presently 2.6 days. Currently, 4.5% of the company's shares are short sold. View PRA Health Sciences' Current Options Chain.

Who are some of PRA Health Sciences' key competitors?

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the folowing people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 59)
  • Ms. Linda Baddour, Exec. VP and Special Advisor to Chairman & CEO (Age 60)
  • Mr. Michael J. Bonello, Exec. VP & CFO
  • Christine Rogers, Director of PR & Corp. Communications
  • Mr. Patrick R. Spine, VP of HR

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Has PRA Health Sciences been receiving favorable news coverage?

Media headlines about PRAH stock have trended somewhat positive on Sunday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PRA Health Sciences earned a media sentiment score of 0.24 on Accern's scale. They also gave media headlines about the medical research company an impact score of 44.90 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include NN Investment Partners Holdings N.V. (0.48%), Scout Investments Inc. (0.12%), Fred Alger Management Inc. (0.10%), Bellecapital International Ltd. (0.10%), Retirement Systems of Alabama (0.10%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

Which major investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Bank of Montreal Can, NN Investment Partners Holdings N.V. and Scout Investments Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

Which major investors are buying PRA Health Sciences stock?

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Bellecapital International Ltd., Louisiana State Employees Retirement System, Municipal Employees Retirement System of Michigan, First National Bank of Hutchinson, State of Alaska Department of Revenue, Amalgamated Bank and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $102.52.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $6.57 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]


MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  445
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.